Oral nano-curcumin in management of COVID-19 patients: An open label nonrandomized clinical trial
Curcumin is proposed as a potential treatment option for coronavirus disease-19 (COVID-19).
An open-label non-randomized clinical trial evaluated the efficacy of nano-curcumin oral formulation in 41 hospitalized patients with mild-moderate COVID-19. Subjects were allocated to nano-curcumin (n = 21; Sinacurcumin soft gel, contains 40 mg curcuminoids as nanomicelles, two capsules twice a day) or control (n = 20) group, for 2 weeks. Patients’ symptoms and laboratory data were assessed at baseline and during follow-up period.
Most of symptoms including fever and chills, tachypnea, myalgia, and cough resolved significantly faster in curcumin group. Moreover, SaO2 was significantly higher in treatment group from day 2 during the follow-up and lymphocyte count after 7 and 14 days. Duration of supplemental O2 use and hospitalization was shorter in treatment group. No patient in treatment group experienced deterioration of infection during follow-up period, but it occurred in 40% of control group.
Therefore, an oral curcumin nano-formulation can significantly improve recovery time in hospitalized COVID-19 patients.
Saber-Moghaddam N, Salari S, Hejazi S, Amini M, Taherzadeh Z, Eslami S, Rezayat SM, Jaafari MR, Elyasi S. Oral nano-curcumin formulation efficacy in management of mild to moderate hospitalized coronavirus disease-19 patients: An open label nonrandomized clinical trial. Phytother Res. 2021 Jan 3. doi: 10.1002/ptr.7004. Epub ahead of print. PMID: 33389761.